Skip to content
Cofactor Genomics logo

Cofactor Genomics

Cofactor Genomics is a YC Summer 2015 (S15) company. Based in St. Louis, MO, USA. Team of 13.

  • Medical Devices
  • Biotech
  • Diagnostics

About Cofactor Genomics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Cofactor Genomics builds predictive diagnostic tools that help oncologists determine which cancer patients will respond to immunotherapy before treatment begins. Its OncoPrism assay uses RNA-based, multidimensional biomarker modeling to replace single-analyte diagnostics that give clinicians an incomplete picture of tumor response. The technology is being evaluated across 11 solid tumor cancers through the national PREDAPT clinical trial, with the goal of covering half of all cancers diagnosed in the US.

Go-to-market

Cofactor works with medical oncologists, pathologists, and healthcare systems, bringing them in as clinical trial partners through the PREDAPT trial before broader commercial deployment.

From the Y Combinator listing

How Cofactor Genomics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Cofactor closes the precision medicine gap with predictive diagnostics

Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).

Facts

Industry
Healthcare / Healthcare -> Diagnostics
Location
St. Louis, MO, USA
Team size
13
Status
Active
Stage
Growth

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works